Cellular replacement therapy for arrhythmia treatment: early clinical experience.
Clinical and experimental studies have demonstrated the proarrhythmic potential of skeletal myoblast transplantation for repair of infarcted myocardium. The evidence on proarrhythmia following bone marrow-derived stem cells, and particular msenchymal stem cells, transplantation is inconclusive. There are experimental and preliminary clinical data supporting the possibility that mesenchymal stem cell transplantation might exert an anti-arrhythmic action by intervening with myocardial scar remodeling. However, clinical experience is limited.
Katritsis
Demosthenes
D
Department of Cardiology, Athens Euroclinic, 9 Athanassiadou Street, Athens 11521, Greece. dkatritsis@euroclinic.gr
D000818:Animals; D001145:Arrhythmias, Cardiac / Q000628:therapy*; D064987:Cell- and Tissue-Based Therapy / Q000379:methods*; D002986:Clinical Trials as Topic; D022062:Electrophysiologic Techniques, Cardiac; D006801:Humans; D032446:Myoblasts / Q000637:transplantation*; D033581:Stem Cell Transplantation / Q000379:methods